Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 33525; 33525 cream; Lulicon; Lulicon Cream 1%; Lulicon Solution 1%; Lulifin; Luzu; NND-502

Latest Information Update: 02 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nihon Nohyaku
  • Developer Ortho Dermatologics; POLA PHARMA; Sun Pharmaceutical Industries; Tinea Pharmaceuticals Inc
  • Class Antifungals; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mycoses; Tinea corporis; Tinea cruris; Tinea pedis
  • Phase II/III Onychomycosis

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 08 Feb 2016 Launched for Tinea corporis (In children, In adolescents) in Honduras, Dominican Republic (Topical) before February 2016
  • 16 Sep 2015 Antimicrobial data from a in vitro potency study in Onychomycosis released by TOPICA Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top